Recent advances in the management of purpura fulminans;Ou en est-on avec le purpura fulminans?

Archives de Pediatrie

Volumn 5, Issue 10, 1998, Pages 1061-1064

  Huault, G ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Communicable disease control; Haemophilus infections; Meningoccal infections; Pneumococcal infections; Purpura fulminans; Vaccin antimeningococcique purpura; Vaccines, conjugate

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CEFTRIAXONE; DEXAMETHASONE; DOBUTAMINE; ENDOTOXIN; HAEMOPHILUS VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; BACTERIAL VACCINE;

ANTIBIOTIC THERAPY; EDITORIAL; FULMINATING PURPURA; HAEMOPHILUS; HUMAN; HYPOVOLEMIA; MENINGOCOCCOSIS; PATHOPHYSIOLOGY; PROGNOSIS; STREPTOCOCCUS INFECTION; ANAPHYLACTOID PURPURA; CHILD; IMMUNIZATION; IMMUNOLOGY; INFANT; LOBAR PNEUMONIA; PRESCHOOL CHILD; VACCINATION;

BACTERIAL VACCINES; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; PNEUMONIA, PNEUMOCOCCAL; PURPURA, SCHOENLEIN-HENOCH; VACCINATION;

EID: 0032186348     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(99)80001-3     Document Type: Editorial

References (24)

1. Kennedy NJ Duncan AW Acute meningococcaemia: recent advances in management (with particular reference to children) Anaesth Intensive Care 24 1996 197 216
2. Parrillo JE Pathogenetic mechanisms of septic shock N Engl J Med 328 1993 1471 1477
3. Girardin E Grau GE Dayer JM Roux-Lombard P Lambert PH Tumor necrosis factor and interleukin-I in the serum of children with severe infectious purpura N Eng J Med 319 1988 397 400
4. Beutler B Cerami A Cachectin: more than a tumor necrosis factor N Eng J Med 316 1987 379 385
5. Michie HR Manogue KR Spriggs DR Revhaugh A O'Dwyer S Dinarello CA Detection of circulating tumor necrosis factor after endotoxin administration N Eng J Med 318 1988 1481 1486
6. Bone RC Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation Crit Care Med 24 1996 163 172
7. Shoemaker WC Appel PL Kram HB Waxman K Lee TS Prospective trial of supranormal values of survivors as therapeutic goals in highrisk surgical patients Chest 94 1988 1176 1186
8. Gattinoni L Brazzi L Pelosi P Latini R Tognoni G Pesenti A A trial of goaloriented hemodynamic therapy in critically ill patients N Engl J Med 333 1995 1025 1032
9. Fong Y Lowry SF Tumor necrosis factor in the pathophysiology of infection and sepsis Clin Immunol Immunopathol 55 1990 157 170
10. Zeni F Freeman B Natanson C Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment Crit Care Med 25 1997 1095 1100
11. Bone RC Grodzin CJ Balk RA Sepsis: a new hypothesis for pathogenesis of the disease process Chest 112 1997 235 243
12. Kox WJ Bone RC Krausch D Docke WD Kox SN Wauer H Interferon gamma-1b in the treatment of compensatory antiinflammatory response syndrome Arch Intern Med 157 1997 389 393
13. Hepburn A Boeynaems JM Fiers W Dumont JE Modulation of tumor necrosis factoralpha cytotoxicity in L 929 cells by bacterial toxins, hydrocortisone and inhibitors of arachidonic acid metabolism Biochem Biophys Res Commun 149 1987 815 822
14. Harrison LH The worldwide prevention of meningococcal infection. Still an elusive goal JAMA 273 1995 419 421
15. Norhonha CP Struchiner CJ Halloran ME Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a casecontrol study Int J Epidemiol 24 1995 1050 1057
16. Boslego J Garcia J Cruz C Zollinger W Brandt B Ruiz S Efficacy, safety immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique Chile. Chilean National Committee for Meningococcal Disease Vaccine 13 1995 821 829
17. Echeverry Uribe ML Malberty Agüero JA Galeano Marin LA Sotolongo Padron FT Galguera Dominguez MA Montoya Barrientos CM Respuesta immmune humoral a las proteinas de una vacuna antimeningococica BC en un ensayo realizado en Antioquia, Colombia Bol Oficina Sanit Panam 118 1995 285 294
18. O'Dempsey TJD McArdle T Ceesay SJ Secka O Demba E Banya WA Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy Arch Dis Child Fetal Neonatal Ed 74 1996 F43 F46
19. Mendelman PM Feeley L Bird S Staub T Matthews H Del Beccaro MA Immunogenicity and safety of Haemophilus influenzae type b polysaccharide- Neisseria meningitidis conju-gate vaccine in 75 μ g liquid formulation: comparison of three lots with the 150 μ g lyophilized formulation. Study group for the 7,5 μ g Liquid Pedvax HIB Vaccine 15 1997 775 781
20. Leach A Twumasi PA Kumah S Banya WS Jaffar S Forrest BD Induction of immunologic memory in Gambian children by vaccination in infancy with group A plus group C meningo-coccal polysaccharide-protein conjugate vaccine J Infect Dis 175 1997 200 204
21. Fairley CK Begg N Borrow R Fox AJ Jones DM Cartwright K Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immmunogenicity in United Kingdom infants J Infect Dis 174 1996 1360 1363
22. Liebermari JM Chiu SS Wong VK Partidge S Chang Sj Chiu CY Safety and immunogenicity of a serogroups A/C Neis-seria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial JAMA 275 1996 1499 1503
23. Twumasi PA Jr Kumah S Leach A O'Dempsey TJD Ceesay SJ Todd J A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants J Infect Dis 171 1995 632 638
24. Figen CAP Kuijper EJ Tija HG Daha MR Danken J Complement deficiency predisposes for meningitis due to non groupable meningococcia and Neisseria related bacteria Clin Infect Dis 18 1994 780 784